UBS Group initiated coverage on shares of MEDNAX (NYSE:MD) in a research note issued to investors on Friday morning, 99wallstreet.com reports. The brokerage issued a sell rating and a $37.00 target price on the stock.

MD has been the subject of a number of other research reports. Leerink Swann upgraded shares of MEDNAX from a market perform rating to an outperform rating in a research note on Monday, September 24th. ValuEngine upgraded shares of MEDNAX from a strong sell rating to a sell rating in a research note on Friday, August 3rd. Credit Suisse Group decreased their price target on shares of MEDNAX from $55.00 to $50.00 and set an outperform rating for the company in a research note on Tuesday, November 6th. Robert W. Baird decreased their price target on shares of MEDNAX from $48.00 to $40.00 and set a neutral rating for the company in a research note on Friday, November 2nd. Finally, Stifel Nicolaus set a $47.00 price target on shares of MEDNAX and gave the stock a hold rating in a research note on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the stock. MEDNAX has an average rating of Hold and a consensus price target of $51.20.

NYSE MD opened at $39.28 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $3.51 billion, a P/E ratio of 12.47, a P/E/G ratio of 1.05 and a beta of 0.33. MEDNAX has a 12 month low of $37.26 and a 12 month high of $63.04.

MEDNAX (NYSE:MD) last posted its earnings results on Thursday, November 1st. The company reported $0.94 EPS for the quarter, missing the Zacks’ consensus estimate of $0.97 by ($0.03). The company had revenue of $896.60 million during the quarter, compared to analysts’ expectations of $908.15 million. MEDNAX had a net margin of 9.50% and a return on equity of 10.45%. The company’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period last year, the business earned $0.87 earnings per share. On average, research analysts forecast that MEDNAX will post 3.57 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in MD. BlackRock Inc. increased its holdings in shares of MEDNAX by 2.8% in the 3rd quarter. BlackRock Inc. now owns 8,352,351 shares of the company’s stock valued at $389,720,000 after purchasing an additional 227,101 shares in the last quarter. Pzena Investment Management LLC increased its holdings in shares of MEDNAX by 41.5% in the 3rd quarter. Pzena Investment Management LLC now owns 3,254,122 shares of the company’s stock valued at $151,837,000 after purchasing an additional 954,322 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of MEDNAX by 2.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,233,798 shares of the company’s stock valued at $104,226,000 after purchasing an additional 50,806 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of MEDNAX by 39.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,764,948 shares of the company’s stock valued at $82,353,000 after purchasing an additional 500,538 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in shares of MEDNAX by 5.1% in the 2nd quarter. Wells Fargo & Company MN now owns 886,955 shares of the company’s stock valued at $38,389,000 after purchasing an additional 43,426 shares in the last quarter. Institutional investors own 98.51% of the company’s stock.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Further Reading: Determine Your Level of Risk Tolerance

Analyst Recommendations for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.